Skip to main content

COVID-19 Topic Center

News

News
“Persistence with dupilumab therapy was high,” researchers wrote, “and among the few patients who discontinued, more than three-quarters reinitiated treatment within 4 months.”
News
According to study findings, treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone at an intended dose intensity of 80% or higher increased the risk of hospitalization for infection in a cohort of older patients with DLBCL.
News
“Currently, the unmet need for treatment options is high in patients with ankylosing spondylitis, including a need for effective oral treatment options following NSAIDs and a need for additional mechanisms of action,” researchers wrote.
News
The prevalence of metabolic syndrome is significantly higher in patients with psoriatic arthritis compared with patients with ankylosing spondylitis, suggests a new study.
News
Cumulative doses of phototherapy and related costs varied greatly among seven skin diseases, researchers highlighted in a new study.
News
A new report from the Government Accountability Office casts doubt on whether insurers are abiding by federal law requiring parity in insurance coverage, which forbids health plans from passing along more of the bill for mental health care to patients than they would for medical or surgical care.
News
A 35-year-old man with severe erythrodermic atopic dermatitis experienced clearance of his disease after 4 months of adding rescue tofacitinib to dupilumab therapy, according to a recent case report.
News
“Because persistence with the same anti-TNF drug in second-line treatment decreases the overall disease-associated costs compared with non-persistence, this aspect … merits consideration by physicians and payers when choosing a biological drug,” researchers wrote.
News
Researchers recently conducted a network meta-analysis and found treatment with guselkumab for psoriatic arthritis improved patient outcomes.
News
Humana sharply disputed the findings of the audit, and a spokesperson for the company said Humana will work with Medicare officials “to resolve this review,” and noted the recommendations “do not represent final determinations, and Humana will have the right to appeal.”  
Back to Top